284030-58-6

Basic information

• Product Name: METHYL 4-AMINO-2,3-DIFLUORO-5-NITROBENZOATE
• Synonyms: METHYL 4-AMINO-2,3-DIFLUORO-5-NITROBENZOATE;4-AMINO-2,3-DIFLUORO-5-NITRO-BENZOIC ACID METHYL ESTER;4-Nitro-2,3-Difluoro-5-Nitro Benzoic Acid Methyl Ester;Benzoic acid,4-aMino-2,3-difluoro-5-nitro-, Methyl ester;4-amino-2,3-difluoro-5-nitrobenzoate
• CAS NO: 284030-58-6
• Molecular Formula: C₈H₆F₂N₂O₄
• Molecular Weight: 232.14
• Product Categories: Phenylacetic acid
• Mol File: 284030-58-6.mol

Chemical Properties

• Melting Point: 184-186°C
• Boiling Point: 402 °C at 760 mmHg
• Flash Point: 196.9 °C
• Appearance: /
• Density: 1.548 g/cm³
• Vapor Pressure: 1.14E-06mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: -5.22±0.25(Predicted)
• CAS DataBase Reference: METHYL 4-AMINO-2,3-DIFLUORO-5-NITROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-AMINO-2,3-DIFLUORO-5-NITROBENZOATE(284030-58-6)
• EPA Substance Registry System: METHYL 4-AMINO-2,3-DIFLUORO-5-NITROBENZOATE(284030-58-6)

Safety Data

• Hazardous Substances Data: 284030-58-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 4-AMINO-2,3-DIFLUORO-5-NITROBENZOATE is used as an intermediate in the synthesis of anti-cancer, anti-inflammatory, and antimicrobial drugs. Its unique chemical structure allows for the development of novel therapeutic agents with potential applications in treating various diseases and conditions.
Used in Agrochemical Industry:
METHYL 4-AMINO-2,3-DIFLUORO-5-NITROBENZOATE is also used as an intermediate in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural products. Its properties can be leveraged to create effective solutions for pest control and crop protection.
Safety and Handling:
METHYL 4-AMINO-2,3-DIFLUORO-5-NITROBENZOATE should be handled and stored according to standard laboratory procedures to ensure safety and prevent any potential hazards. Proper precautions, such as wearing protective gear and working in a well-ventilated area, should be taken to minimize risks associated with its use.

InChI:InChI=1/C8H6F2N2O4/c1-16-8(13)3-2-4(12(14)15)7(11)6(10)5(3)9/h2H,11H2,1H3

Upstream product

• 186581-53-3 diazomethane 
• 284030-57-5 4-amino-2,3-difluoro-5-nitro-benzoic acid 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 197520-71-1 2,3,4-trifluoro-5-nitro-benzoic acid 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 606143-95-7 4-amino-3-fluoro-2-(2-methyl-4-trifluoromethoxy-phenylamino)-5-nitro-benzoic acid methyl ester 
• 606143-98-0 4-amino-2-(2-chloro-phenylamino)-3-fluoro-5-nitro-benzoic acid methyl ester 
• 284030-59-7 4-Amino-3-fluoro-5-nitro-2-o-tolylamino-benzoic acid methyl ester 
• 918321-18-3 methyl 2,4-diamino-3-fluoro-5-nitrobenzoate 
• 1360624-53-8 2-(2,2,2-trifluoro-ethoxy)-3-fluoro-4-amino-5-nitro-benzoic acid methyl ester 
• 606093-58-7 4-Amino-3-fluoro-5-nitro-2-phenylamino-benzoic acid methyl ester 
• 606143-94-6 4-amino-3-fluoro-2-(2-fluoro-phenylamino)-5-nitro-benzoic acid methyl ester 
• 917980-11-1 4-amino-2,3-difluoro-5-nitrobenzamide 

Relevant articles and documents

FORMS OF BINIMETINIB AND PROCESS FOR PREPARATION THEREOF

Amorphous forms of Binimetinib and processes for the preparation thereof.

Substituted benzimidazole compound and composition with compound

The invention provides a substituted benzimidazole compound and a composition with the compound. The substituted benzimidazole compound is a compound of formula (I) as shown in the specification, or apharmaceutically acceptable salt, prodrug, aquo-complex or solvent compound, polycrystalline type compound, stereisomer or isotope variant of the compound. The compound provided by the invention canbe adopted to treat and/or prevent related diseases caused by MEK (Methyl Ethyl Ketone), such as excessive proliferative diseases, pancreatitis, kidney illness, blastocyte cell transplantation and angiogenesis or angiopoiesis related diseases.

COMBINATION THERAPY

The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)- amide or a pharmaceutically acceptable salt thereof and the IGFIR inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.

SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-2 and their synthetic intermediates: wherein X1, X2, X5, R1, R2 and R4 are as defined herein. Compounds of Formula Ia-2 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.

PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-1 and their synthetic intermediates: wherein Z, X1, X2, X5, R2 and R10 are as defined herein. Compounds of Formula Ia-1 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.

NOVEL HYDROGEN SULFATE SALT

The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. Compound I

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, t, R1, R2, R7, R9, R10, R11 and R12 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.